Redeye views Optomed’s cEUR1.8m order from a US-based screening service provider and distributor positively. While the order does not include any recurring revenue component, we believe it should help ease market concerns following the weak Q1 2026 report. In addition, the order strengthens confidence in our forecasts for the Devices segment, and we reiterate our valuation of the company.
LÄS MER
